Gastrointestinal Cancer Drugs Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Gastrointestinal Cancer Drugs Market Trends and Insights

Precision Oncology and Biomarker Defined Treatment Adoption

The gastrointestinal cancer drugs market is increasingly driven by biomarker-based treatment decisions rather than tumor location alone. Colorectal, gastric, and pancreatic cancer care uses KRAS G12C, BRAF V600E, HER2, CLDN18.2, MSI-H/dMMR, MET amplification, and NRG1 fusions. Commercially relevant targets have nearly tripled since 2020. Patients can transition to another biomarker-eligible regimen after disease progression, extending treatment across multiple lines of care. In 2026, the FDA approved Guardant360 CDx as a companion diagnostic for the BRAFTOVI combination in BRAF V600E-mutant metastatic colorectal cancer, supporting liquid biopsy adoption and testing access in community oncology settings.

First Line Immunotherapy Combination Expansion

First-line checkpoint inhibitor combinations are replacing chemotherapy alone across several gastrointestinal cancers. In March 2025, the FDA approved pembrolizumab with trastuzumab and platinum-based chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma with PD-L1 CPS of 1 or higher. In April 2025, nivolumab plus ipilimumab received regular approval for first-line MSI-H/dMMR unresectable or metastatic colorectal cancer. These regimens require biomarker testing at the start of care and can extend maintenance treatment for 24 months or longer. The FDA approval of the Idylla CDx MSI Test for nivolumab in dMMR colorectal cancer also supported an automated workflow with results in under three hours.

Rising Gastrointestinal Cancer Burden and Earlier Diagnosis

The growing disease burden provides sustained demand for the gastrointestinal cancer drugs market. Pancreatic cancer incidence is projected to increase by 95% by 2050, the fastest increase among gastrointestinal cancer types.^{[1]International Agency for Research on Cancer, “Global Burden of Gastrointestinal Cancers,” Cancer Today, iarc.who.int} Colorectal cancer deaths are projected to increase by 103%, making it the largest contributor to future gastrointestinal cancer deaths in absolute terms. Population aging, obesity, and sedentary lifestyles are increasing the treatment-eligible population. In the United States, colorectal screening eligibility was extended to age 45, potentially increasing stage II and III diagnoses where adjuvant treatment is relevant. Africa is projected to record a 157% increase in incidence and a 160% increase in gastrointestinal cancer deaths by 2050, despite limited oncology care capacity.

Perioperative and Adjuvant Drug Treatment

Treatment before and after surgery is expanding the role of systemic medicines beyond metastatic disease. In 2026, the European Union approved durvalumab with FLOT perioperative chemotherapy for resectable stage II to IVA gastric and gastroesophageal junction cancer. The FDA approved the same treatment setting in November 2025. These regimens can introduce 12 to 24 months of treatment around surgery for patients who previously received surgery and chemotherapy. In August 2026, Chugai Pharmaceutical submitted a Japanese application for atezolizumab as adjuvant treatment for MSI-H/dMMR stage III colon cancer, based on the ATOMIC trial. Broader perioperative treatment use also favors hospitals and integrated oncology networks that coordinate surgery, diagnostics, infusion care, and follow-up.

Cost and Reimbursement Friction for Biomarker Selected Regimens

Biomarker-selected combinations are among the highest-cost treatment options in gastrointestinal oncology. First-line treatment for HER2-positive gastric adenocarcinoma can combine HER2-targeted therapy, PD-1 or PD-L1 inhibition, and chemotherapy. Health technology assessment bodies assess these combinations against incremental survival gains, which may be measured in weeks rather than months. In several European countries, reimbursement for medicines does not always cover companion diagnostics, discouraging testing and limiting biomarker-eligible prescribing. China’s 2025 National Reimbursement Drug List process included several gastrointestinal cancer biologics and required price cuts of 40% to 60% for inclusion.^{[2]China National Healthcare Security Administration, “2025 National Reimbursement Drug List Adjustment Application Materials,” China National Healthcare Security Administration, nhsa.gov.cn} Wider coverage can improve access, but lower prices can reduce manufacturer margins and favor domestic products with lower starting prices.

Biosimilar, Generic, and Mandatory Price Reduction Pressure

Trastuzumab, bevacizumab, and cetuximab have long been core biologics in gastrointestinal cancer care, but biosimilar competition is reducing branded revenue in Europe, Japan, and China. In June 2026, Roche received IVDR approval for the VENTANA MMR RxDx Panel for companion diagnostic use across colorectal and gastric cancers, including pembrolizumab-related indications. The approval supports consistent testing and clarifies testing requirements for future competing products. Japan approved sotorasib plus panitumumab for KRAS G12C colorectal cancer in September 2025. 

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Cancer Type: Colorectal Cancer Leads While Pancreatic Cancer Expands

Colorectal cancer held 34.22% of the gastrointestinal cancer drugs market share in 2025, supported by established treatment pathways across biomarker-defined groups, including MSI-H/dMMR, BRAF V600E, KRAS G12C, and HER2-amplified disease. Gastric, gastroesophageal junction, and esophageal cancers formed the next-largest group, with treatment use increasing following HER2-directed and PD-1 inhibitor approvals in 2025 and 2026. Pancreatic cancer is the fastest-growing category, with the segment projected to grow at a 5.36% CAGR through 2031. In August 2026, the FDA is expected to approve daraxonrasib for metastatic pancreatic adenocarcinoma after prior systemic therapy or for patients unable to receive multi-agent chemotherapy. The Phase III RASolute 302 trial showed a 60% reduction in the risk of death versus chemotherapy.

Daraxonrasib is expected to become the first targeted RAS inhibitor approved for pancreatic cancer, expanding targeted therapy in an indication previously dominated by chemotherapy. Merus received FDA accelerated approval for zenocutuzumab in NRG1 fusion-positive pancreatic adenocarcinoma in December 2024. In May 2026, the FDA expanded the use of zenocutuzumab to NRG1 fusion-positive cholangiocarcinoma following prior systemic therapy. Liver, anal, and other gastrointestinal cancers retain smaller shares but have approved systemic treatment options. 

By Application: Oncology Departments Remain Central While Radiology Expands

Oncology departments accounted for 68.76% of gastrointestinal cancer drug spending in 2025, reflecting the use of infusion-based immunotherapy and chemotherapy in established oncology settings. Radiology and nuclear medicine are projected to grow at a 6.33% CAGR through 2031, the fastest rate across the application segment. Radioligand therapies require specialized administration environments beyond standard infusion services. These therapies require radiation safety certification, shielded preparation areas, and waste-disposal procedures subject to nuclear regulations. Such requirements limit early expansion to centers with established infrastructure. The other application category, including supportive care drugs, dose-limiting agents, and radiation-sensitizing compounds, retains a comparatively stable share.

The gastrointestinal cancer drugs market is adding distribution, training, and access requirements as radioligand programs advance. Manufacturers need programs tailored to nuclear medicine settings rather than only infusion centers. Approved radioligand approaches in neuroendocrine tumors provide a foundation for future expansion across other gastrointestinal malignancies. Investigational programs could increase radiology activity as additional indications receive regulatory clearance. The FDA’s accelerated review pathways for breakthrough-designated radioligand therapies can reduce the time from clinical results to adoption in care settings. However, specialized infrastructure remains a practical constraint on near-term patient volumes.

By Therapy: Immunotherapy Leads While Targeted Therapy Gains Use

Immunotherapy held 58.60% of the gastrointestinal cancer drugs market share in 2025. Its broad use reflects checkpoint inhibitor approvals across gastric, colorectal, esophageal, and hepatocellular carcinoma. These therapies are used as first-line treatments, in combination with chemotherapy or HER2-targeted medicines, before surgery, during surgery, and after surgery. Targeted therapy is projected to grow at a 6.56% CAGR through 2031, making it the fastest-growing therapy type. Approvals in 2025 and 2026 expanded the molecular subgroups eligible for targeted treatment. The FDA approved sotorasib with panitumumab for chemorefractory KRAS G12C-mutated metastatic colorectal cancer in January 2025 and granted full approval to the BRAFTOVI combination for first-line BRAF V600E metastatic colorectal cancer in 2026.

In August 2026, the FDA is expected to approve zanidatamab with tislelizumab and fluoropyrimidine- or platinum-based chemotherapy for first-line HER2-positive advanced gastroesophageal adenocarcinoma. During the same month, Daraxonrasib is expected to create a targeted treatment option for RAS-mutant pancreatic cancer. Companion diagnostic co-approval requirements make diagnostic capacity critical to treatment initiation. Chemotherapy retains a substantial role in combination regimens, although its standalone role is declining. Cellular therapy, tumor-infiltrating lymphocyte therapy, and radioligand therapy remain small categories, but late-stage Phase III data could support broader use. Hormone therapy remains a limited option for rare hormonally responsive gastrointestinal tumors.

By End User: Hospitals Lead While Ambulatory Centers Grow

Hospitals held 53.56% of gastrointestinal cancer drug revenue in 2025. They maintain an advantage in administering complex intravenous regimens, including anti-PD-1 combinations, antibody-drug conjugate infusions, and radioligand treatments. These medicines may require multi-hour administration and clinical monitoring. Oncology clinics are the second-largest end-user group, providing community infusion and oral chemotherapy services. Ambulatory Surgical Centers are projected to grow at a 5.77% CAGR through 2031. Their expansion follows the increasing use of oral targeted therapies, including daraxonrasib, sotorasib, encorafenib, and cabozantinib.

Providers can initiate and manage these therapies in ambulatory settings with periodic monitoring. Cancer research institutes represent a smaller but important part of the gastrointestinal cancer drugs market, serving as key sites for clinical trial treatment, early-access programs, and expanded-access protocols. Oral therapies are shifting care from infusion centers toward ambulatory and pharmacy-based dispensing channels. This shift can reduce follow-up visits compared with infusion-based treatment while increasing the importance of adherence monitoring. Manufacturers are responding through patient support programs and digital health partnerships. Ambulatory and outpatient pharmacy settings may reduce total care costs, even when oral medicines have higher list prices.

Geography Analysis

North America held a 39.44% share of the gastrointestinal cancer drugs market in 2025. The region benefited from more than 10 FDA clearances for gastrointestinal cancer therapies between January 2025 and August 2026. The United States led the region due to higher drug prices, stronger biomarker testing rates, and formulary systems that rapidly cover new approvals. Canada and Mexico held smaller but growing positions, while the Inflation Reduction Act price negotiation framework may pressure U.S. pricing advantages as eligible oncology medicines reach nine years after approval.

Europe held a significant market share, led by Germany, France, the United Kingdom, Italy, and Spain. The EU IVDR framework increased compliance requirements and concentrated companion diagnostic activity among larger certified suppliers. Roche’s VENTANA MMR RxDx Panel received IVDR approval in June 2026 for several gastrointestinal cancer indications. The European approval of durvalumab with FLOT added a perioperative treatment option for resectable gastric and gastroesophageal junction cancer, although health technology assessment decisions may delay access in Germany and France.

Asia-Pacific is projected to expand at a CAGR of 6.98% through 2031, making it the fastest-growing geographic segment. Rising cancer incidence, investments in domestic biologics production, and faster regulatory reviews support growth. China approved VYLOY for CLDN18.2-positive gastric cancer in January 2025 and Enhertu for second-line HER2-positive gastric cancer in January 2026. Japan approved sotorasib with panitumumab in September 2025 and updated the Enhertu label in March 2026. The Middle East and Africa and South America remain smaller contributors, although Africa’s projected 157% increase in cancer incidence indicates long-term potential.